secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-128993
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO
----------------------------------------------------------------------

- Usman Azam resigned as President, CEO and Board member effective March 26, 2026.
- Lucinda Warren, previously CFO and CBO, appointed Interim President and CEO effective March 27, 2026; retains CFO and CBO roles.
- Warren's base salary $525,000; eligible for 45% target bonus and up to 1.0% stock option upon financing milestone.
- Azam severance: lump sum $232,500 (3 months salary plus 25% of 2026 target bonus) plus up to 12 months COBRA.
- Warren receives $10,000/month supplemental until new CEO hired or 12-month anniversary, with lump sum if earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526128993/0001193125-26-128993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526128993/d120770d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-128993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer